Abstract
In sharp contrast to the branded pharmaceutical market, which has stalled in
recent year, the generics market is enjoying a period of unprecedented
success. In 2005 the world generics market was worth $45bn, a growth of 14% on
the previous year. Visiongain expects this level of growth to continue over
the forecast period of this report.
The loss of patent protection by 2009 of almost $80bn worth of top selling
drugs will be the major driving force for this generic market growth.
Additionally, as healthcare costs in the developed world continue to increase,
and the growth of pharmaceutical markets in developing countries continues to
grow. More generic copies of successful drugs are being sold worldwide than
ever before. This report describes how this burgeoning market will change over
the forecast period and highlights the important issues for both originator
companies and generic drugs manufacturers.
What is the therapeutic area with the most potential for generic companies?
How are branded pharmaceutical companies preparing for the increasing threat
of generic penetration? What challenges do generic companies face in the
coming years? Read visiongain's The World Generics Market 2006-2011 report to
find out.
The following issues are covered in detail:
- A summary of the relevant legislation affecting the generics industry
- A market forecast for the world generics market 2006-2011
- An assessment of the drivers and restraints of the market during this
period
- A discussion of the attitudes to generics in different regions including
the US, Europe and Asia
- The issue of Biogenerics and the changes in regulations required for their
success
- A review of strategies for success for originator and generics companies
Why should you buy this report?
The progress of the generic pharmaceutical market is of great importance to
anyone in the pharmaceutical industry. This report provides detailed financial
data and invaluable opinion about how this market will change over the
important period to come.
| 
View Cart
